Search

Your search keyword '"Ogasawara, Sadahisa"' showing total 319 results
Start Over Author "Ogasawara, Sadahisa" Search Limiters Full Text
319 results on '"Ogasawara, Sadahisa"'

1. Risk factors of unintentional piecemeal resection in endoscopic mucosal resection for colorectal polyps ≥ 10 mm

Author

Ishikawa, Tsubasa, Okimoto, Kenichiro, Matsumura, Tomoaki, Ogasawara, Sadahisa, Fukuda, Yoshihiro, Kitsukawa, Yoshio, Yokoyama, Yuya, Kanayama, Kengo, Akizue, Naoki, Iino, Yotaro, Ohta, Yuki, Ishigami, Hideaki, Taida, Takashi, Tsuchiya, Shin, Saito, Keiko, Kamezaki, Hidehiro, Kobayashi, Akitoshi, Kikuchi, Yasuharu, Tada, Minoru, Shiko, Yuki, Ozawa, Yoshihito, Kato, Jun, Yamaguchi, Taketo, and Kato, Naoya

Published
2024
Full Text
View/download PDF

2. Cabozantinib for Advanced Hepatocellular Carcinoma in the Latest Real-World Practice: A Multicenter Retrospective Analysis

Author

Kanzaki, Hiroaki, Ogasawara, Sadahisa, Okubo, Tomomi, Itokawa, Norio, Yoshino, Ryohei, Fujimoto, Kentaro, Kogure, Tadayoshi, Yumita, Sae, Ishino, Takamasa, Ogawa, Keita, Iwanaga, Terunao, Nakagawa, Miyuki, Fujiwara, Kisako, Kojima, Ryuta, Koroki, Keisuke, Inoue, Masanori, Kobayashi, Kazufumi, Kanogawa, Naoya, Kiyono, Soichiro, Nakamura, Masato, Kondo, Takayuki, Nakagawa, Ryo, Nakamoto, Shingo, Muroyama, Ryosuke, Itobayashi, Ei, Atsukawa, Masanori, Kato, Jun, and Kato, Naoya

Published
2023
Full Text
View/download PDF

4. Potential of circulating receptor-interacting protein kinase 3 levels as a marker of acute liver injury

Author

Kondo, Takayuki, Fujimoto, Kentaro, Fujiwara, Kisako, Yumita, Sae, Ishino, Takamasa, Ogawa, Keita, Nakagawa, Miyuki, Iwanaga, Terunao, Koroki, Keisuke, Kanzaki, Hiroaki, Inoue, Masanori, Kobayashi, Kazufumi, Kiyono, Soichiro, Nakamura, Masato, Kanogawa, Naoya, Ogasawara, Sadahisa, Nakamoto, Shingo, Chiba, Tetsuhiro, Kato, Jun, Fujiwara, Keiichi, and Kato, Naoya

Published
2023
Full Text
View/download PDF

5. Treatment strategy changes for inflammatory bowel diseases in biologic era: results from a multicenter cohort in Japan, Far East 1000

Author

Taida, Takashi, Ohta, Yuki, Kato, Jun, Ogasawara, Sadahisa, Ohyama, Yuhei, Mamiya, Yukiyo, Nakazawa, Hayato, Horio, Ryosuke, Goto, Chihiro, Takahashi, Satsuki, Kurosugi, Akane, Sonoda, Michiko, Shiratori, Wataru, Kaneko, Tatsuya, Yokoyama, Yuya, Akizue, Naoki, Iino, Yotaro, Kumagai, Junichiro, Ishigami, Hideaki, Koseki, Hirotaka, Okimoto, Kenichiro, Saito, Keiko, Saito, Masaya, Matsumura, Tomoaki, Nakagawa, Tomoo, Okabe, Shinichiro, Saito, Hirofumi, Kato, Kazuki, Uehara, Hirotsugu, Mizumoto, Hideaki, Koma, Yoshihiro, Azemoto, Ryosaku, Ito, Kenji, Kamezaki, Hidehiro, Mandai, Yoshifumi, Masuya, Yoshio, Fukuda, Yoshihiro, Kitsukawa, Yoshio, Shimura, Haruhisa, Tsuyuguchi, Toshio, and Kato, Naoya

Published
2023
Full Text
View/download PDF

6. Estimation of the effect of atezolizumab plus bevacizumab on pulmonary arterial hypertension using computed tomography in HCC patients

Author

Kondo, Takayuki, Fujiwara, Kisako, Nakagawa, Miyuki, Fujimoto, Kentaro, Yumita, Sae, Ishino, Takamasa, Ogawa, Keita, Iwanaga, Terunao, Koroki, Keisuke, Kanzaki, Hiroaki, Inoue, Masanori, Kobayashi, Kazufumi, Kiyono, Soichiro, Nakamura, Masato, Kanogawa, Naoya, Ogasawara, Sadahisa, Nakamoto, Shingo, Chiba, Tetsuhiro, Kato, Jun, and Kato, Naoya

Published
2023
Full Text
View/download PDF

8. Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma

Author

Kanogawa, Naoya, Ogasawara, Sadahisa, Maruta, Susumu, Iino, Yotaro, Obu, Masamichi, Ishino, Takamasa, Ogawa, Keita, Yumita, Sae, Iwanaga, Terunao, Unozawa, Hidemi, Nakagawa, Miyuki, Fujiwara, Kisako, Sakuma, Takafumi, Fujita, Naoto, Kojima, Ryuta, Kanzaki, Hiroaki, Koroki, Keisuke, Kobayashi, Kazufumi, Inoue, Masanori, Kiyono, Soichiro, Nakamura, Masato, Kondo, Takayuki, Saito, Tomoko, Nakagawa, Ryo, Nakamoto, Shingo, Muroyama, Ryosuke, Chiba, Tetsuhiro, Itobayashi, Ei, Koma, Yoshihiro, Azemoto, Ryosaku, Kato, Jun, and Kato, Naoya

Published
2023
Full Text
View/download PDF

9. Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice

Author

Yumita, Sae, Ogasawara, Sadahisa, Nakagawa, Miyuki, Maruta, Susumu, Okubo, Tomomi, Itokawa, Norio, Iino, Yotaro, Obu, Masamichi, Haga, Yuki, Seki, Atsuyoshi, Kogure, Tadayoshi, Ishino, Takamasa, Ogawa, Keita, Fujiwara, Kisako, Iwanaga, Terunao, Fujita, Naoto, Sakuma, Takafumi, Kojima, Ryuta, Kanzaki, Hiroaki, Koroki, Keisuke, Inoue, Masanori, Kobayashi, Kazufumi, Kiyono, Soichiro, Nakamura, Masato, Kanogawa, Naoya, Saito, Tomoko, Kondo, Takayuki, Nakagawa, Ryo, Nakamoto, Shingo, Muroyama, Ryosuke, Chiba, Tetsuhiro, Itobayashi, Ei, Atsukawa, Masanori, Koma, Yoshihiro, Azemoto, Ryosaku, Ito, Kenji, Mizumoto, Hideaki, Kato, Jun, and Kato, Naoya

Published
2023
Full Text
View/download PDF

10. A diet-induced murine model for non-alcoholic fatty liver disease with obesity and insulin resistance that rapidly develops steatohepatitis and fibrosis

Author

Sakuma, Takafumi, Nakamura, Masato, Chiba, Tetsuhiro, Iwanaga, Terunao, Kan, Motoyasu, Kojima, Ryuta, Ao, Junjie, Ma, Yaojia, Unozawa, Hidemi, Fujita, Naoto, Kanayama, Kengo, Kanzaki, Hiroaki, Koroki, Keisuke, Kobayashi, Kazufumi, Nakagawa, Ryo, Kanogawa, Naoya, Kiyono, Soichiro, Kondo, Takayuki, Saito, Tomoko, Ogasawara, Sadahisa, Nakamoto, Shingo, Muroyama, Ryosuke, Kato, Jun, Kishimoto, Takashi, and Kato, Naoya

Published
2022
Full Text
View/download PDF

12. “Salvage techniques” are the key to overcome difficult biliary cannulation in endoscopic retrograde cholangiopancreatography

Author

Maruta, Shikiko, Sugiyama, Harutoshi, Ogasawara, Sadahisa, Sugihara, Chihei, Ouchi, Mayu, Kan, Motoyasu, Yamada, Toshihito, Miura, Yoshifumi, Nagashima, Hiroki, Takahashi, Koji, Kusakabe, Yuko, Ohyama, Hiroshi, Okitsu, Koichiro, Ohno, Izumi, Mikata, Rintaro, Sakai, Yuji, Tsuyuguchi, Toshio, Kato, Jun, and Kato, Naoya

Published
2022
Full Text
View/download PDF

13. The efficacy of contrast-enhanced computed tomography on the management of gastroesophageal varices in patients with hepatocellular carcinoma

Author

Kondo, Takayuki, Fujiwara, Kisako, Nakagawa, Miyuki, Unozawa, Hidemi, Iwanaga, Terunao, Sakuma, Takafumi, Fujita, Naoto, Koroki, Keisuke, Kanzaki, Hiroaki, Kobayashi, Kazufumi, Kiyono, Soichiro, Nakamura, Masato, Kanogawa, Naoya, Saito, Tomoko, Ogasawara, Sadahisa, Suzuki, Eiichiro, Ooka, Yoshihiko, Nakamoto, Shingo, Chiba, Tetsuhiro, Arai, Makoto, Kato, Jun, and Kato, Naoya

Published
2022
Full Text
View/download PDF

14. The long-term effect of biologics in patients with ulcerative colitis emerging from a large Japanese cohort

Author

Yokoyama, Yuya, Ohta, Yuki, Ogasawara, Sadahisa, Kato, Jun, Arai, Ryoko, Koseki, Hirotaka, Saito, Masaya, Kaneko, Tatsuya, Tokunaga, Mamoru, Oura, Hirotaka, Oike, Tsubasa, Imai, Yushi, Kanayama, Kengo, Akizue, Naoki, Kumagai, Junichiro, Taida, Takashi, Okimoto, Kenichiro, Saito, Keiko, Ooka, Yoshihiko, Matsumura, Tomoaki, Nakagawa, Tomoo, Arai, Makoto, Katsuno, Tatsuro, Fukuda, Yoshihiro, Kitsukawa, Yoshio, and Kato, Naoya

Published
2022
Full Text
View/download PDF

15. Assessment of Macrovascular Invasion in Advanced Hepatocellular Carcinoma: Clinical Implications and Treatment Outcomes with Systemic Therapy

Author

Inoue, Masanori, primary, Ogasawara, Sadahisa, additional, Kobayashi, Kazufumi, additional, Okubo, Tomomi, additional, Itokawa, Norio, additional, Obu, Masamichi, additional, Fujimoto, Kentaro, additional, Unozawa, Hidemi, additional, Yumita, Sae, additional, Fujiwara, Kisako, additional, Nakagawa, Miyuki, additional, Kanzaki, Hiroaki, additional, Koroki, Keisuke, additional, Kiyono, Soichiro, additional, Nakamura, Masato, additional, Kanogawa, Naoya, additional, Kondo, Takayuki, additional, Nakamoto, Shingo, additional, Nagashima, Kengo, additional, Itobayashi, Ei, additional, Atsukawa, Masanori, additional, Koma, Yoshihiro, additional, Azemoto, Ryosaku, additional, and Kato, Naoya, additional

Published
2024
Full Text
View/download PDF

16. EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma

Author

Kusakabe, Yuko, Chiba, Tetsuhiro, Oshima, Motohiko, Koide, Shuhei, Rizq, Ola, Aoyama, Kazumasa, Ao, Junjie, Kaneko, Tatsuya, Kanzaki, Hiroaki, Kanayama, Kengo, Maeda, Takahiro, Saito, Tomoko, Nakagawa, Ryo, Kobayashi, Kazufumi, Kiyono, Soichiro, Nakamura, Masato, Ogasawara, Sadahisa, Suzuki, Eiichiro, Nakamoto, Shingo, Yasui, Shin, Mikata, Rintaro, Muroyama, Ryosuke, Kanda, Tatsuo, Maruyama, Hitoshi, Kato, Jun, Mimura, Naoya, Ma, Anqi, Jin, Jian, Zen, Yoh, Otsuka, Masayuki, Kaneda, Atsushi, Iwama, Atsushi, and Kato, Naoya

Published
2021
Full Text
View/download PDF

17. The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma

Author

Kanzaki, Hiroaki, Chiba, Tetsuhiro, Ao, Junjie, Koroki, Keisuke, Kanayama, Kengo, Maruta, Susumu, Maeda, Takahiro, Kusakabe, Yuko, Kobayashi, Kazufumi, Kanogawa, Naoya, Kiyono, Soichiro, Nakamura, Masato, Kondo, Takayuki, Saito, Tomoko, Nakagawa, Ryo, Ogasawara, Sadahisa, Suzuki, Eiichiro, Ooka, Yoshihiko, Muroyama, Ryosuke, Nakamoto, Shingo, Yasui, Shin, Tawada, Akinobu, Arai, Makoto, Kanda, Tatsuo, Maruyama, Hitoshi, Mimura, Naoya, Kato, Jun, Zen, Yoh, Ohtsuka, Masayuki, Iwama, Atsushi, and Kato, Naoya

Published
2021
Full Text
View/download PDF

18. T1 Mapping Enabled Detection and Follow-up of Rare Immune Checkpoint Inhibitor Myocarditis

Author

Nishikawa, Yusei, primary, Takaoka, Hiroyuki, additional, Kanda, Masato, additional, Yumita, Sae, additional, Ogasawara, Sadahisa, additional, Daimon, Michiko, additional, Noguchi, Yoshitada, additional, Aoki, Shuhei, additional, Suzuki, Katsuya, additional, Yoshida, Kazuki, additional, Yashima, Satomi, additional, Kinoshita, Makiko, additional, Sasaki, Haruka, additional, Suzuki-Eguchi, Noriko, additional, Kato, Naoya, additional, and Kobayashi, Yoshio, additional

Published
2023
Full Text
View/download PDF

19. A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study

Author

Kobayashi, Kazufumi, primary, Ogasawara, Sadahisa, additional, Maruta, Susumu, additional, Okubo, Tomomi, additional, Itokawa, Norio, additional, Haga, Yuki, additional, Seko, Yuya, additional, Moriguchi, Michihisa, additional, Watanabe, Shunji, additional, Shiko, Yuki, additional, Takatsuka, Hirokazu, additional, Kanzaki, Hiroaki, additional, Koroki, Keisuke, additional, Inoue, Masanori, additional, Nakamura, Masato, additional, Kiyono, Soichiro, additional, Kanogawa, Naoya, additional, Kondo, Takayuki, additional, Suzuki, Eiichiro, additional, Ooka, Yoshihiko, additional, Nakamoto, Shingo, additional, Inaba, Yosuke, additional, Ikeda, Masafumi, additional, Okabe, Shinichiro, additional, Morimoto, Naoki, additional, Itoh, Yoshito, additional, Nakamura, Kazuyoshi, additional, Ito, Kenji, additional, Azemoto, Ryosaku, additional, Atsukawa, Masanori, additional, Itobayashi, Ei, additional, and Kato, Naoya, additional

Published
2023
Full Text
View/download PDF

21. Practicality of STAT3 Gene Polymorphisms and Sorafenib Trough Concentration as Biomarkers for Sorafenib-Induced Hand-Foot Skin Reaction in Hepatocellular Carcinoma

Author

Takatsuka, Hirokazu, primary, Sugawara, Takato, additional, Uchida, Masashi, additional, Yamazaki, Shingo, additional, Suzuki, Takaaki, additional, Kanogawa, Naoya, additional, Ogasawara, Sadahisa, additional, Shiko, Yuki, additional, Kawasaki, Yohei, additional, Kato, Naoya, additional, and Ishii, Itsuko, additional

Published
2023
Full Text
View/download PDF

22. Multicenter Phase II Trial of Lenvatinib plus Hepatic Intra-Arterial Infusion Chemotherapy with Cisplatin for Advanced Hepatocellular Carcinoma: LEOPARD

Author

Ikeda, Masafumi, primary, Yamashita, Tatsuya, additional, Ogasawara, Sadahisa, additional, Kudo, Masatoshi, additional, Inaba, Yoshitaka, additional, Morimoto, Manabu, additional, Tsuchiya, Kaoru, additional, Shimizu, Satoshi, additional, Kojima, Yasushi, additional, Hiraoka, Atsushi, additional, Nouso, Kazuhiro, additional, Aikata, Hiroshi, additional, Numata, Kazushi, additional, Sato, Tosiya, additional, Okusaka, Takuji, additional, and Furuse, Junji, additional

Published
2023
Full Text
View/download PDF

23. Multicenter Phase II Trial of Lenvatinib plus Hepatic Intra-Arterial Infusion Chemotherapy with Cisplatin for Advanced Hepatocellular Carcinoma: LEOPARD.

Author

Ikeda, Masafumi, Yamashita, Tatsuya, Ogasawara, Sadahisa, Kudo, Masatoshi, Inaba, Yoshitaka, Morimoto, Manabu, Tsuchiya, Kaoru, Shimizu, Satoshi, Kojima, Yasushi, Hiraoka, Atsushi, Nouso, Kazuhiro, Aikata, Hiroshi, Numata, Kazushi, Sato, Tosiya, Okusaka, Takuji, and Furuse, Junji

Subjects
INTRA-arterial infusions, CISPLATIN, HEPATOCELLULAR carcinoma, CLINICAL trials, OVERALL survival
Abstract

Introduction: Hepatic arterial infusion chemotherapy (HAIC) with cisplatin and lenvatinib exhibits strong antitumor effects against advanced hepatocellular carcinoma (HCC). Higher antitumor activity is expected for the combination treatment. The aim of this trial was to evaluate the efficacy and safety of lenvatinib in combination with HAIC using cisplatin in patients with advanced HCC. Methods: In this multicenter, open-labeled, single-arm, phase II trial, patients with advanced HCC categorized as Child-Pugh class A with no prior history of systemic therapy were enrolled. Patients received lenvatinib plus HAIC with cisplatin (lenvatinib: 12 mg once daily for patients ≥60 kg, 8 mg once daily for patients <60 kg; HAIC with cisplatin: 65 mg/m2, day 1, every 4–6 weeks, maximum of six cycles). The primary endpoint was the objective response rate (ORR) assessed using modified RECIST by the Independent Review Committee. The secondary endpoints were the ORR assessed using RECIST v1.1, progression-free survival, overall survival, and frequency of adverse events associated with the treatment. Results: A total of 36 patients were enrolled between September 2018 and March 2020. In the 34 evaluable patients, the ORR assessed by the Independent Review Committee using modified RECIST and RECIST v1.1 were 64.7% (95% confidence interval [CI]: 46.5–80.3%) and 45.7% (95% CI: 28.8–63.4%), respectively. The median progression-free survival and overall survival were 6.3 months (95% CI: 5.1–7.9 months) and 17.2 months (95% CI: 10.9 – not available, months), respectively. The main grade 3–4 adverse events were increased aspartate aminotransferase (34%), leukopenia (22%), increased alanine aminotransferase (19%), and hypertension (11%). Conclusion: Lenvatinib plus HAIC with cisplatin yielded a favorable ORR and overall survival and was well tolerated in patients with advanced HCC. Further evaluation of this regimen in a phase III trial is warranted. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Impact of skeletal muscle volume on patients with BCLC stage‐B hepatocellular carcinoma undergoing sorafenib therapy

Author

Saeki, Issei, primary, Yamasaki, Takahiro, additional, Yamauchi, Yurika, additional, Kawaoka, Tomokazu, additional, Uchikawa, Shinsuke, additional, Hiramatsu, Akira, additional, Aikata, Hiroshi, additional, Kobayashi, Kazufumi, additional, Kondo, Takayuki, additional, Ogasawara, Sadahisa, additional, Chiba, Tetsuhiro, additional, Kawano, Reo, additional, Chayama, Kazuaki, additional, Kato, Naoya, additional, and Takami, Taro, additional

Published
2023
Full Text
View/download PDF

27. Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer-Term Follow-Up From the Phase 3 KEYNOTE-240 Trial

Author

Merle, Philippe, primary, Kudo, Masatoshi, additional, Edeline, Julien, additional, Bouattour, Mohamed, additional, Cheng, Ann-Lii, additional, Chan, Stephen Lam, additional, Yau, Thomas, additional, Garrido, Marcelo, additional, Knox, Jennifer, additional, Daniele, Bruno, additional, Breder, Valeriy, additional, Lim, Ho Yeong, additional, Ogasawara, Sadahisa, additional, Cattan, Stéphane, additional, Chao, Yee, additional, Siegel, Abby B., additional, Martinez-Forero, Iván, additional, Wei, Ziwen, additional, Liu, Chih-Chin, additional, and Finn, Richard S., additional

Published
2023
Full Text
View/download PDF

28. Antiviral Compounds Screening Targeting HBx Protein of the Hepatitis B Virus

Author

Ma, Yaojia, primary, Nakamoto, Shingo, additional, Ao, Junjie, additional, Qiang, Na, additional, Kogure, Tadayoshi, additional, Ogawa, Keita, additional, Nakagawa, Miyuki, additional, Fujiwara, Kisako, additional, Iwanaga, Terunao, additional, Kojima, Ryuta, additional, Kanzaki, Hiroaki, additional, Koroki, Keisuke, additional, Kobayashi, Kazufumi, additional, Kanogawa, Naoya, additional, Kiyono, Soichiro, additional, Nakamura, Masato, additional, Kondo, Takayuki, additional, Nakagawa, Ryo, additional, Ogasawara, Sadahisa, additional, Muroyama, Ryosuke, additional, Chiba, Tetsuhiro, additional, Kato, Jun, additional, and Kato, Naoya, additional

Published
2022
Full Text
View/download PDF

31. Controlling Major Portal Vein Invasion Progression during Lenvatinib Treatment by Carbon-Ion Radiotherapy in Patients with Advanced Hepatocellular Carcinoma

Author

Yoshida, Ryoi, Koroki, Keisuke, Makishima, Hirokazu, Ogasawara, Sadahisa, Ishino, Takamasa, Ogawa, Keita, Nakagawa, Miyuki, Fujiwara, Kisako, Hidemi Unozawa, Iwanaga, Terunao, Fujita, Naoto, Sakuma, Takafumi, Kanzaki, Hiroaki, Kobayashi, Kazufumi, Kanogawa, Naoya, Kiyono, Soichiro, Nakamura, Masato, Kondo, Takayuki, Saito, Tomoko, Nakagawa, Ryo, Suzuk, Eiichiro, Ooka, Yoshihiko, Nakamoto, Shingo, Tawada, Akinobu, Chiba, Tetsuhiro, Arai, Makoto, Kaneko, Takashi, Wakatsuki, Masaru, Kato, Jun, Tsuji, Hiroshi, Kato, Naoya, Hirokazu, Makishima, Keita, Ogawa, Naoto, Fujita, Naoya, Kanogawa, Tomoko, Saitou, Takashi, Kaneko, Masaru, Wakatsuki, and Hiroshi, Tsuji

Abstract

Macrovascular invasion (MVI), including portal vein tumor thrombosis (PVTT), is strongly associated with poor prognosis in patients with hepatocellular carcinoma (HCC). While recommended standard treatment for patients with advanced HCC is systemic therapy, various treatment approaches, including resection, transarterial chemoembolization, and radiation, have been empirically suggested to improve prognosis by eliminating or controlling MVI. Herein, we report our experience of a case with advanced HCC where MVI was controlled by carbon-ion radiotherapy (CIRT) while on systemic therapy, resulting in a prolonged survival. A female patient with HCC in her early 60s had multiple intrahepatic lesions (maximum 60 mm in diameter) with PVTT. The PVTT of this patient had reached the main trunk of the portal vein despite the use of lenvatinib. The other intrahepatic lesions of the patient, except PVTT, had been controlled by lenvatinib. Therefore, hoping to control PVTT, we attempted CIRT. The patient resumed lenvatinib therapy after the irradiation. During lenvatinib re-treatment, no evident progression of PVTT was observed in the patient.

Published
2021

32. MO5-1 Regorafenib in advanced HCC patients who were not included in the RESORCE trial: first interim analysis

Author

Koroki, Keisuke, primary, Ogasawara, Sadahisa, additional, Terunao, Iwanaga, additional, Unozawa, Hidemi, additional, Fujiwara, Kisako, additional, Nakagawa, Miyuki, additional, Sakuma, Takafumi, additional, Fujita, Naoto, additional, Kanzaki, Hiroaki, additional, Kobayashi, Kazufumi, additional, Kiyono, Soichiro, additional, Nakamura, Masato, additional, Kanogawa, Naoya, additional, Saito, Tomoko, additional, Kondo, Takayuki, additional, Nakagawa, Ryo, additional, Nakamoto, Shingo, additional, Muroyama, Ryosuke, additional, Chiba, Tetsuhiro, additional, and Kato, Naoya, additional

Published
2022
Full Text
View/download PDF

33. A case of hepatocellular carcinoma followed by asynchronous metastasis to the lung and thoracic spine following radical ablation treatment

Author

Kato Naoya, Saito Tomoko, Kanogawa Naoya, Kato Jun, Ooka Yoshihiko, Nakamoto Shingo, Suzuki Eiichiro, Kusakabe Yuko, Maruta Susumu, Kondo Takayuki, Maruyama Hitoshi, Kobayashi Kazufumi, Yoshino Ichiro, Kanda Tatsuro, Chiba Tetsuhiro, Nakamura Masato, Tawada Akinobu, Kiyono Soichiro, Ogasawara Sadahisa, Kanzaki Hiroaki, Kanayama Kengo, Kooroki Keisuke, Sakuma Takafumi, and Kishimoto Takashi

Subjects
medicine.medical_specialty, Thesaurus (information retrieval), Lung, Hepatology, business.industry, Thoracic spine, medicine.medical_treatment, Ablation, medicine.disease, Metastasis, medicine.anatomical_structure, Hepatocellular carcinoma, medicine, Radiology, business
Published
2021
Full Text
View/download PDF

34. Phase Ib trial of durvalumab plus tremelimumab in combination with particle radiotherapy in advanced hepatocellular carcinoma patients with macrovascular invasion: DEPARTURE trial

Author

Ogasawara, Sadahisa, Koroki, Keisuke, Hirokazu, Makishima, Masaru, Wakatsuki, Sakuma, Takafumi, Naoto, Fujita, Kanzaki, Hiroaki, Kobayashi, Kazufumi, Kiyono, Souichiro, Masato, Nakamura, Naoya, Kanogawa, Tomoko, Saitou, Kondo, Takayuki, Nakagawa, Ryo, Nakamoto, Shingo, Muroyama, Ryosuke, Chiba, Tetsuhiro, Hideki, Hanaoka, Hiroshi, Tsuji, Kato, Naoya, Ogasawara, Sadahisa, Koroki, Keisuke, Hirokazu, Makishima, Masaru, Wakatsuki, Sakuma, Takafumi, Naoto, Fujita, Kanzaki, Hiroaki, Kobayashi, Kazufumi, Kiyono, Souichiro, Masato, Nakamura, Naoya, Kanogawa, Tomoko, Saitou, Kondo, Takayuki, Nakagawa, Ryo, Nakamoto, Shingo, Muroyama, Ryosuke, Chiba, Tetsuhiro, Hideki, Hanaoka, Hiroshi, Tsuji, and Kato, Naoya

Abstract

Background: Advanced hepatocellular carcinoma (HCC) with macrovascular invasion (MVI) has the worst prognosis among all HCC cases, due to its uniqueness of disease condition. Development of revolutionary therapeutic approaches to improve prognosis in these patients is an essential medical issue. A phase I/II trial demonstrated that treatment with durvalumab, an anti-programmed death-ligand 1 antibody, alone or in combination with tremelimumab, an anti-cytotoxic T-lymphocyte antigen 4 antibody, exhibited potential efficacy in patients with advanced HCC. Conversely, particle radiotherapy, including carbon-ion radiotherapy, has been shown to achieve unique dose distribution by delivering high-dose radiation to the target tumor while reducing the radiation dose to normal tissues due to its physical characteristics. Studies demonstrated that particle radiotherapy could achieve good local control in patients with HCC, including those with MVI. Additionally, particle radiotherapy as well as photon irradiation not only mediate localized tumor killing but also modify the tumor microenvironment, thereby potentiating the efficacy of immune checkpoint inhibitors. The DEPARTURE trial aims to evaluate whether treatment with durvalumab, alone or in combination with tremelimumab, plus particle radiotherapy is a safe and synergistically effective treatment in patients with advanced HCC and MVI. Methods: This is a phase Ib, multi-center, open-label, single-arm, investigator-initiated clinical trial to assess the safety of durvalumab monotherapy in combination with particle radiotherapy (Cohort A) and that of durvalumab plus tremelimumab in combination with particle radiotherapy (Cohort B) in advanced HCC patients with MVI who are ineligible for standard systemic therapy and Child–Pugh A liver disease. Cohort A will receive 1500 mg durvalumab every four weeks in principle. Cohort B will receive 1500 mg durvalumab every four weeks in principle and 300 mg tremelimumab only on day 1 of t

Published
2022

35. Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial

Author

Verset, Gontran, Borbath, Ivan, Karwal, Mark, Verslype, Chris, Van Vlierberghe, Hans, Kardosh, Adel, Zagonel, Vittorina, Stal, Per, Sarker, Debashis, Palmer, Daniel D.H., Vogel, Arndt, Edeline, Julien, Cattan, Stéphane, Kudo, Masatoshi, Cheng, Ann Lii, Ogasawara, Sadahisa, Daniele, Bruno, Chan, Stephen Lam, Knox, Jennifer, Qin, Shukui, Siegel, Abby A.B., Chisamore, Michael, Hatogai, Ken, Wang, Anran, Finn, Richard R.S., Zhu, Andrew Xiuxuan, Verset, Gontran, Borbath, Ivan, Karwal, Mark, Verslype, Chris, Van Vlierberghe, Hans, Kardosh, Adel, Zagonel, Vittorina, Stal, Per, Sarker, Debashis, Palmer, Daniel D.H., Vogel, Arndt, Edeline, Julien, Cattan, Stéphane, Kudo, Masatoshi, Cheng, Ann Lii, Ogasawara, Sadahisa, Daniele, Bruno, Chan, Stephen Lam, Knox, Jennifer, Qin, Shukui, Siegel, Abby A.B., Chisamore, Michael, Hatogai, Ken, Wang, Anran, Finn, Richard R.S., and Zhu, Andrew Xiuxuan

Abstract

Purpose: KEYNOTE-224 cohort 1 demonstrated that pembrolizumab was efficacious and tolerable in patients with advanced hepatocellular carcinoma (HCC) previously treated with sorafenib. We report results from KEYNOTE-224 (NCT02702414) cohort 2, which enrolled patients with advanced HCC and no prior systemic therapy. Patients and Methods: KEYNOTE-224 was an open-label, multicountry phase II trial. Eligible patients in cohort 2 had advanced HCC not amenable or refractory to locoregional therapy and not previously treated with systemic therapy. Patients received pembrolizumab 200 mg intravenously every 3 weeks for ≤2 years. Primary endpoint was objective response rate (ORR) by central imaging review per RECIST v1.1. Secondary endpoints included duration of response (DOR), disease control rate (DCR), time to progression (TTP), progression-free survival (PFS), overall survival (OS), and safety/tolerability. Results: Between September 4, 2018, and February 20, 2019, 51 patients were allocated in cohort 2. The median time from the first dose to data cutoff (January 19, 2021) was 27 months (range, 23-29). ORR was 16% [95% confidence interval (CI), 7-29] and was similar across key subgroups. Median DOR was 16 months (range, 3-24+), and DCR was 57%. The median PFS was 4 months (95% CI, 2-8), and median TTP was 4 months (95% CI, 3-9). Median OS was 17 months (95% CI, 8-23). Grade ≥3 treatment-related adverse events occurred in 16% of patients. Conclusions: In patients with advanced HCC with no prior systemic therapy, pembrolizumab provided durable antitumor activity, promising OS, and had a safety profile consistent with previous observations. These findings support further evaluation of pembrolizumab-based regimens for HCC., SCOPUS: re.j, info:eu-repo/semantics/published

Published
2022

36. Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib

Author

Kudo, Masatoshi, Finn, Richard R.S., Edeline, Julien, Cattan, Stéphane, Ogasawara, Sadahisa, Palmer, Daniel D.H., Verslype, Chris, Zagonel, Vittorina, Fartoux, Laetitia, Vogel, Arndt, Sarker, Debashis, Verset, Gontran, Chan, Stephen Lam, Knox, Jennifer, Daniele, Bruno, Yau, Thomas, Gurary, Ellen E.B., Siegel, Abby A.B., Wang, Anran, Cheng, Ann Lii, Zhu, Andrew Xiuxuan, Kudo, Masatoshi, Finn, Richard R.S., Edeline, Julien, Cattan, Stéphane, Ogasawara, Sadahisa, Palmer, Daniel D.H., Verslype, Chris, Zagonel, Vittorina, Fartoux, Laetitia, Vogel, Arndt, Sarker, Debashis, Verset, Gontran, Chan, Stephen Lam, Knox, Jennifer, Daniele, Bruno, Yau, Thomas, Gurary, Ellen E.B., Siegel, Abby A.B., Wang, Anran, Cheng, Ann Lii, and Zhu, Andrew Xiuxuan

Abstract

Objective: Pembrolizumab, a PD-1 inhibitor, demonstrated anti-tumour activity and tolerability in patients treated with sorafenib and with advanced hepatocellular carcinoma in KEYNOTE-224. Longer-term efficacy and safety after ∼2.5 years of additional follow-up are reported. Patients and methods: Adults with confirmed hepatocellular carcinoma who experienced progression after or intolerance to sorafenib treatment received pembrolizumab 200 mg every 3 weeks for ≤35 cycles or until confirmed progression, unacceptable toxicity, withdrawal of consent or investigator decision. The primary end-point was objective response rate assessed by blinded independent central review per Response Evaluation Criteria in Solid Tumours v1.1. The secondary end-points included duration of response, disease control rate, time to progression, progression-free survival, overall survival and adverse events. Results: Efficacy and safety were assessed in 104 patients. The median time from first dose to data cutoff was 45.1 months (range, 41.3–49.3). Objective response rate was 18.3% (95% CI: 11.4–27.1), and median duration of response was 21.0 months (range, 3.1 to 39.5+). Disease control rate was 61.5%, and median time to progression was 4.8 months (95% CI: 3.9–7.0). Median progression-free survival was 4.9 months (95% CI: 3.5–6.7) and median overall survival was 13.2 months (95% CI: 9.7–15.3). Of 104 patients, 76 (73.1%) patients reported treatment-related adverse events; most were low grade in severity (grade 3–4, n = 26 [25.0%]; grade 5, n = 1 [1.0%]). Immune-mediated hepatitis occurred in 3 patients (all grade 3). No viral-induced hepatitis flares occurred. Conclusions: After ∼2.5 years of additional follow-up, pembrolizumab continued to provide durable anti-tumour activity and no new safety concerns were identified. ClinicalTrials.gov identifier: NCT02702414., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2022

37. Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial

Author

Verset, Gontran, primary, Borbath, Ivan, additional, Karwal, Mark, additional, Verslype, Chris, additional, Van Vlierberghe, Hans, additional, Kardosh, Adel, additional, Zagonel, Vittorina, additional, Stal, Per, additional, Sarker, Debashis, additional, Palmer, Daniel H., additional, Vogel, Arndt, additional, Edeline, Julien, additional, Cattan, Stephane, additional, Kudo, Masatoshi, additional, Cheng, Ann-Lii, additional, Ogasawara, Sadahisa, additional, Daniele, Bruno, additional, Chan, Stephen L., additional, Knox, Jennifer J., additional, Qin, Shukui, additional, Siegel, Abby B., additional, Chisamore, Michael, additional, Hatogai, Ken, additional, Wang, Anran, additional, Finn, Richard S., additional, and Zhu, Andrew X., additional

Published
2022
Full Text
View/download PDF

38. Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial

Author

Ogasawara, Sadahisa, primary, Koroki, Keisuke, additional, Makishima, Hirokazu, additional, Wakatsuki, Masaru, additional, Takahashi, Asahi, additional, Yumita, Sae, additional, Nakagawa, Miyuki, additional, Ishino, Takamasa, additional, Ogawa, Keita, additional, Fujiwara, Kisako, additional, Iwanaga, Terunao, additional, Sakuma, Takafumi, additional, Fujita, Naoto, additional, Kojima, Ryuta, additional, Kanzaki, Hiroaki, additional, Kobayashi, Kazufumi, additional, Kiyono, Soichiro, additional, Nakamura, Masato, additional, Kanogawa, Naoya, additional, Saito, Tomoko, additional, Kondo, Takayuki, additional, Nakagawa, Ryo, additional, Nakamoto, Shingo, additional, Muroyama, Ryosuke, additional, Chiba, Tetsuhiro, additional, Ozawa, Yoshihito, additional, Kawasaki, Yohei, additional, Kurokawa, Tomoya, additional, Hanaoka, Hideki, additional, Tsuji, Hiroshi, additional, and Kato, Naoya, additional

Published
2022
Full Text
View/download PDF

39. Impact of acute decompensation on the prognosis of patients with hepatocellular carcinoma

Author

Kondo, Takayuki, primary, Koroki, Keisuke, additional, Kanzaki, Hiroaki, additional, Kobayashi, Kazufumi, additional, Kiyono, Soichiro, additional, Nakamura, Masato, additional, Kanogawa, Naoya, additional, Saito, Tomoko, additional, Ogasawara, Sadahisa, additional, Ooka, Yoshihiko, additional, Nakamoto, Shingo, additional, Chiba, Tetsuhiro, additional, Arai, Makoto, additional, Kato, Jun, additional, Kuboki, Satoshi, additional, Ohtsuka, Masayuki, additional, and Kato, Naoya, additional

Published
2022
Full Text
View/download PDF

40. Management of Systemic Therapies and Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma Based on Sarcopenia Assessment

Author

Yamasaki, Takahiro, primary, Saeki, Issei, additional, Yamauchi, Yurika, additional, Matsumoto, Toshihiko, additional, Suehiro, Yutaka, additional, Kawaoka, Tomokazu, additional, Uchikawa, Shinsuke, additional, Hiramatsu, Akira, additional, Aikata, Hiroshi, additional, Kobayashi, Kazufumi, additional, Kondo, Takayuki, additional, Ogasawara, Sadahisa, additional, Chiba, Tetsuhiro, additional, Takami, Taro, additional, Chayama, Kazuaki, additional, Kato, Naoya, additional, and Sakaida, Isao, additional

Published
2022
Full Text
View/download PDF

41. Effect of Atezolizumab plus Bevacizumab in Patients with Hepatocellular Carcinoma Harboring CTNNB1 Mutation in Early Clinical Experience

Author

Ogawa, Keita, primary, Kanzaki, Hiroaki, additional, Chiba, Tetsuhiro, additional, Ao, Junjie, additional, Qiang, Na, additional, Ma, Yaojia, additional, Zhang, Jiaqi, additional, Yumita, Sae, additional, Ishino, Takamasa, additional, Unozawa, Hidemi, additional, Kan, Motoyasu, additional, Iwanaga, Terunao, additional, Nakagawa, Miyuki, additional, Fujiwara, Kisako, additional, Fujita, Naoto, additional, Sakuma, Takafumi, additional, Koroki, Keisuke, additional, Kusakabe, Yuko, additional, Kobayashi, Kazufumi, additional, Kanogawa, Naoya, additional, Kiyono, Soichiro, additional, Nakamura, Masato, additional, Kondo, Takayuki, additional, Saito, Tomoko, additional, Nakagawa, Ryo, additional, Ogasawara, Sadahisa, additional, Suzuki, Eiichiro, additional, Nakamoto, Shingo, additional, Muroyama, Ryosuke, additional, Kanda, Tatsuo, additional, Maruyama, Hitoshi, additional, Mimura, Naoya, additional, Kato, Jun, additional, Motohashi, Shinichiro, additional, and Kato, Naoya, additional

Published
2022
Full Text
View/download PDF

42. Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma

Author

Kobayashi, Kazufumi, primary, Ogasawara, Sadahisa, additional, Takahashi, Aya, additional, Seko, Yuya, additional, Unozawa, Hidemi, additional, Sato, Rui, additional, Watanabe, Shunji, additional, Moriguchi, Michihisa, additional, Morimoto, Naoki, additional, Tsuchiya, Satoshi, additional, Iwai, Kenji, additional, Inoue, Masanori, additional, Ogawa, Keita, additional, Ishino, Takamasa, additional, Iwanaga, Terunao, additional, Sakuma, Takafumi, additional, Fujita, Naoto, additional, Kanzaki, Hiroaki, additional, Koroki, Keisuke, additional, Nakamura, Masato, additional, Kanogawa, Naoya, additional, Kiyono, Soichiro, additional, Kondo, Takayuki, additional, Saito, Tomoko, additional, Nakagawa, Ryo, additional, Suzuki, Eiichiro, additional, Ooka, Yoshihiko, additional, Nakamoto, Shingo, additional, Tawada, Akinobu, additional, Chiba, Tetsuhiro, additional, Arai, Makoto, additional, Kanda, Tatsuo, additional, Maruyama, Hitoshi, additional, Nagashima, Kengo, additional, Kato, Jun, additional, Isoda, Norio, additional, Aramaki, Takeshi, additional, Itoh, Yoshito, additional, and Kato, Naoya, additional

Published
2021
Full Text
View/download PDF

43. Exploring microsatellite instability in patients with advanced hepatocellular carcinoma and its tumor microenvironment

Author

Mukai, Shohei, primary, Kanzaki, Hiroaki, additional, Ogasawara, Sadahisa, additional, Ishino, Takamasa, additional, Ogawa, Keita, additional, Nakagawa, Miyuki, additional, Fujiwara, Kisako, additional, Unozawa, Hidemi, additional, Iwanaga, Terunao, additional, Sakuma, Takafumi, additional, Fujita, Naoto, additional, Koroki, Keisuke, additional, Kobayashi, Kazufumi, additional, Kanogawa, Naoya, additional, Kiyono, Soichiro, additional, Nakamura, Masato, additional, Kondo, Takayuki, additional, Saito, Tomoko, additional, Nakagawa, Ryo, additional, Suzuki, Eiichiro, additional, Ooka, Yoshihiko, additional, Muroyama, Ryosuke, additional, Nakamoto, Shingo, additional, Tawada, Akinobu, additional, Chiba, Tetsuhiro, additional, Arai, Makoto, additional, Kato, Jun, additional, Shiina, Manayu, additional, Ota, Masayuki, additional, Ikeda, Jun‐ichiro, additional, Takiguchi, Yuichi, additional, Ohtsuka, Masayuki, additional, and Kato, Naoya, additional

Published
2021
Full Text
View/download PDF

44. MO38-1 The latest procedure of liver biopsy in the era of cancer genomic therapies; the single center retrospective analysis

Author

Ozeki, Yusuke, primary, Kanogawa, Naoya, additional, Iwanaga, Terunao, additional, Fujita, Naoto, additional, Sakuma, Takafumi, additional, Kanzaki, Hiroaki, additional, Koroki, Keisuke, additional, Kobayashi, Kazufumi, additional, Kiyono, Soichiro, additional, Nakamura, Masato, additional, Saito, Tomoko, additional, Kondo, Takayuki, additional, Ogasawara, Sadahisa, additional, Suzuki, Eiichiro, additional, Nakamoto, Shingo, additional, Tawada, Akinobu, additional, Chiba, Tetsuhiro, additional, Arai, Makoto, additional, Kato, Jun, additional, Takiguchi, Yuichi, additional, and Kato, Naoya, additional

Published
2021
Full Text
View/download PDF

45. Management of Hepatocellular Carcinoma in Japan : JSH Consensus Statements and Recommendations 2021 Update

Author

Kudo, Masatoshi, Kawamura, Yusuke, Hasegawa, Kiyoshi, Tateishi, Ryosuke, Kariyama, Kazuya, Shiina, Shuichiro, Toyoda, Hidenori, Imai, Yasuharu, Hiraoka, Atsushi, Ikeda, Masafumi, Izumi, Namiki, Moriguchi, Michihisa, Ogasawara, Sadahisa, Minami, Yasunori, Ueshima, Kazuomi, Murakami, Takamichi, Miyayama, Shiro, Nakashima, Osamu, Yano, Hirohisa, Sakamoto, Michiie, Hatano, Etsuro, Shimada, Mitsuo, Kokudo, Norihiro, Mochida, Satoshi, Takehara, Tetsuo, Kudo, Masatoshi, Kawamura, Yusuke, Hasegawa, Kiyoshi, Tateishi, Ryosuke, Kariyama, Kazuya, Shiina, Shuichiro, Toyoda, Hidenori, Imai, Yasuharu, Hiraoka, Atsushi, Ikeda, Masafumi, Izumi, Namiki, Moriguchi, Michihisa, Ogasawara, Sadahisa, Minami, Yasunori, Ueshima, Kazuomi, Murakami, Takamichi, Miyayama, Shiro, Nakashima, Osamu, Yano, Hirohisa, Sakamoto, Michiie, Hatano, Etsuro, Shimada, Mitsuo, Kokudo, Norihiro, Mochida, Satoshi, and Takehara, Tetsuo

Abstract

The Clinical Practice Manual for Hepatocellular Carcinoma was published based on evidence confirmed by the Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma along with consensus opinion among a Japan Society of Hepatology (JSH) expert panel on hepatocellular carcinoma (HCC). Since the JSH Clinical Practice Guidelines are based on original articles with extremely high levels of evidence, expert opinions on HCC management in clinical practice or consensus on newly developed treatments are not included. However, the practice manual incorporates the literature based on clinical data, expert opinion, and real-world clinical practice currently conducted in Japan to facilitate its use by clinicians. Alongside each revision of the JSH Guidelines, we issued an update to the manual, with the first edition of the manual published in 2007, the second edition in 2010, the third edition in 2015, and the fourth edition in 2020, which includes the 2017 edition of the JSH Guideline. This article is an excerpt from the fourth edition of the HCC Clinical Practice Manual focusing on pathology, diagnosis, and treatment of HCC. It is designed as a practical manual different from the latest version of the JSH Clinical Practice Guidelines. This practice manual was written by an expert panel from the JSH, with emphasis on the consensus statements and recommendations for the management of HCC proposed by the JSH expert panel. In this article, we included newly developed clinical practices that are relatively common among Japanese experts in this field, although all of their statements are not associated with a high level of evidence, but these practices are likely to be incorporated into guidelines in the future. To write this article, coauthors from different institutions drafted the content and then critically reviewed each other’s work. The revised content was then critically reviewed by the Board of Directors and the Planning and Public Relations Committee of JSH b

Published
2021

48. Skeletal Muscle Volume Is an Independent Predictor of Survival after Sorafenib Treatment Failure for Hepatocellular Carcinoma

Author

Saeki, Issei, primary, Yamasaki, Takahiro, additional, Yamauchi, Yurika, additional, Takami, Taro, additional, Kawaoka, Tomokazu, additional, Uchikawa, Shinsuke, additional, Hiramatsu, Akira, additional, Aikata, Hiroshi, additional, Kawano, Reo, additional, Kobayashi, Kazufumi, additional, Kondo, Takayuki, additional, Ogasawara, Sadahisa, additional, Chiba, Tetsuhiro, additional, Chayama, Kazuaki, additional, Kato, Naoya, additional, and Sakaida, Isao, additional

Published
2021
Full Text
View/download PDF

49. Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma.

Author

Kudo, Masatoshi, Ueshima, Kazuomi, Ikeda, Masafumi, Torimura, Takuji, Tanabe, Nobukazu, Aikata, Hiroshi, Izumi, Namiki, Yamasaki, Takahiro, Nojiri, Shunsuke, Hino, Keisuke, Tsumura, Hidetaka, Kuzuya, Teiji, Isoda, Norio, Moriguchi, Michihisa, Aino, Hajime, Ido, Akio, Kawabe, Naoto, Nakao, Kazuhiko, Wada, Yoshiyuki, and Ogasawara, Sadahisa

Subjects
CHEMOEMBOLIZATION, HEPATOCELLULAR carcinoma, SORAFENIB, LIVER cancer, PROGRESSION-free survival, DISEASE progression
Abstract

Introduction: Several clinical trials comparing the efficacy and safety of transarterial chemoembolization (TACE) plus molecular-targeted agents versus TACE alone revealed no clinical benefits in progression-free survival (PFS) or overall survival (OS). Here, we report the final OS analysis from the TACTICS trial, which previously demonstrated significant improvement in PFS with TACE plus sorafenib in patients with unresectable hepatocellular carcinoma (HCC) (NCT01217034). Methods: Patients with unresectable HCC were randomized to a TACE plus sorafenib group (N = 80) or a TACE alone group (N = 76). Patients in the combination treatment group received sorafenib 400 mg once daily for 2–3 weeks before TACE, followed by 800 mg once daily during on-demand conventional TACE sessions until time to untreatable progression. In this trial, TACE-specific PFS was used. TACE-specific PFS is defined as the time from randomization to progressive disease (PD) or death from any cause, and PD was defined as untreatable progression, caused by the inability of a patient to further receive or benefit from TACE for reasons that include intrahepatic tumor progression (25% increase vs. baseline) according to response evaluation criteria in cancer of the liver, the detection of extrahepatic spread, vascular invasion, or transient deterioration of liver function to Child-Pugh C after TACE. Results: At the cut-off date of July 31, 2020, 131 OS events were observed. The median OS was 36.2 months with TACE plus sorafenib and 30.8 months with TACE alone (hazard ratio [HR] = 0.861; 95% confidence interval [CI], 0.607–1.223; p = 0.40, ΔOS, 5.4 months). The updated PFS was 22.8 months with TACE plus sorafenib and 13.5 months with TACE alone (HR = 0.661; 95% CI, 0.466–0.938; p = 0.02). Post-trial treatments with active procedures/agents were received by 47 (58.8%) patients in the TACE plus sorafenib group and 58 (76.3%) in the TACE alone group (p = 0.01). In post hoc analysis, PFS and OS benefit were shown in HCC patients with tumor burden beyond up-to-7 criteria. Conclusions: In TACTICS trial, TACE plus sorafenib did not show significant OS benefit over TACE alone; however, clinical meaningful OS prolongation and significantly improved PFS was observed. Thus, the TACE plus sorafenib can be considered a choice of treatment in intermediate-stage HCC, especially in patients with high tumor burden. Trial Registration: NCT01217034. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

50. Serum Angiopoietin 2 acts as a diagnostic and prognostic biomarker in hepatocellular carcinoma

Author

Ao, Junjie, primary, Chiba, Tetsuhiro, additional, Kanzaki, Hiroaki, additional, Kanayama, Kengo, additional, Shibata, Shuhei, additional, Kurosugi, Akane, additional, Iwanaga, Terunao, additional, Kan, Motoyasu, additional, Sakuma, Takafumi, additional, Qiang, Na, additional, Ma, Yaojia, additional, Kojima, Ryuta, additional, Kusakabe, Yuko, additional, Nakamura, Masato, additional, Kobayashi, Kazufumi, additional, Kiyono, Soichiro, additional, Kanogawa, Naoya, additional, Saito, Tomoko, additional, Nakagawa, Ryo, additional, Kondo, Takayuki, additional, Ogasawara, Sadahisa, additional, Suzuki, Eiichiro, additional, Nakamoto, Shingo, additional, Muroyama, Ryosuke, additional, Tawada, Akinobu, additional, Kato, Jun, additional, Kanda, Tatsuo, additional, Maruyama, Hitoshi, additional, and Kato, Naoya, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results